Figure 1
Figure 1. Effect of dasatinib on human platelet aggregation and tyrosine phosphorylation on thrombin or collagen stimulation. Platelets from healthy donors were treated or not with increasing concentrations of dasatinib for 15 minutes and stimulated with (A) thrombin, (B) ADP, or (C) collagen. Platelet aggregation was assessed using a Chrono-log dual-channel aggregometer under stirring at 900g. The aggregation profiles shown are representative of 3 independent experiments. Right panels show the effect of dasatinib on whole platelet tyrosine phosphorylation pattern in response to thrombin or collagen. Results are representative of 3 independent experiments. (D) Western blot analysis of phospho-Src family (Tyr416) in human platelets incubated with increasing doses of dasatinib and stimulated by 2.5 μg/mL collagen for 3 minutes. The Western blots shown are representative of 3 independent experiments.

Effect of dasatinib on human platelet aggregation and tyrosine phosphorylation on thrombin or collagen stimulation. Platelets from healthy donors were treated or not with increasing concentrations of dasatinib for 15 minutes and stimulated with (A) thrombin, (B) ADP, or (C) collagen. Platelet aggregation was assessed using a Chrono-log dual-channel aggregometer under stirring at 900g. The aggregation profiles shown are representative of 3 independent experiments. Right panels show the effect of dasatinib on whole platelet tyrosine phosphorylation pattern in response to thrombin or collagen. Results are representative of 3 independent experiments. (D) Western blot analysis of phospho-Src family (Tyr416) in human platelets incubated with increasing doses of dasatinib and stimulated by 2.5 μg/mL collagen for 3 minutes. The Western blots shown are representative of 3 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal